Akelos

Executive Summary

Akelos is a private biotechnology company headquartered in San Francisco, CA, founded in 2019 with a mission to develop novel small molecule therapeutics targeting historically undruggable protein-protein interactions (PPIs) for oncology and other diseases. By focusing on key intracellular interactions that drive disease pathogenesis, Akelos aims to unlock new treatment paradigms beyond conventional drug targets. The company's platform leverages deep expertise in structural biology and medicinal chemistry to design inhibitors that modulate PPIs with high specificity and potency. Although still in early stages, Akelos has built a pipeline of proprietary programs addressing high-value oncology targets. The company operates in a competitive but rapidly evolving PPI space, where recent technological advances have begun to yield clinical candidates. Akelos's approach holds promise for first-in-class therapies, but the inherent challenges of PPI drug discovery mean that preclinical validation and early clinical data will be critical de-risking milestones. The company's private status limits public visibility, but its focus on undruggable targets positions it as a potential acquisition target or partnership opportunity for larger pharma seeking innovative modalities. Near-term success hinges on advancing lead programs toward candidate nomination and securing additional financing to sustain research efforts.

Upcoming Catalysts (preview)

• Q3 2026Lead optimization completion and development candidate nomination for lead PPI program70% success
• Q4 2026Series B financing round to advance pipeline toward IND50% success
• Q2 2026Presentation of preclinical in vivo efficacy data for lead program at a major scientific conference60% success